These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 4751259)

  • 61. Acridinyl anisidide (m-AMSA) therapy in 11 patients with refractory acute leukemia.
    Naparstek E; Shinar E; Polliack A
    Isr J Med Sci; 1984 Feb; 20(2):118-22. PubMed ID: 6546740
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antitumor activity of amygdalin MF (NSC-15780) as a single agent and with beta-glucosidase (NSC-128056) on a spectrum of transplantable rodent tumors.
    Wodinsky I; Swiniarski JK
    Cancer Chemother Rep; 1975; 59(5):939-50. PubMed ID: 1203898
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy.
    Hiddemann W; Martin WR; Sauerland CM; Heinecke A; Büchner T
    Leukemia; 1990 Mar; 4(3):184-8. PubMed ID: 2314117
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparison of enzymatic activities of two deoxycytidine kinases purified from cells sensitive (P815) or resistant (P815/ara-C) to 1-beta-D-arabinofuranosylcytosine.
    Meyers MB; Kreis W
    Cancer Res; 1978 Apr; 38(4):1105-12. PubMed ID: 25131
    [No Abstract]   [Full Text] [Related]  

  • 65. Peroral therapy with cytosine arabinoside. Preliminary laboratory and clinical findings.
    Goldenberg DM; Schricker KT; von der Emde J; Sögtrop HH
    Arzneimittelforschung; 1968 Jun; 18(6):712-4. PubMed ID: 5755808
    [No Abstract]   [Full Text] [Related]  

  • 66. Approaches to leukemic relapse following bone marrow transplantation.
    Gale RP
    Transplant Proc; 1978 Mar; 10(1):167-71. PubMed ID: 345557
    [No Abstract]   [Full Text] [Related]  

  • 67. The effect of thioguanine on a combination of daunorubicine, cytarabine and prednisone in the treatment of acute leukaemia in adults. The Finnish Leukaemia Group.
    Scand J Haematol; 1979 Aug; 23(2):124-8. PubMed ID: 291122
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prolongation of mouse skin allograft survival by treatment with cytosine arabinoside in combination with F 1 hybrid lymphocytes.
    Amaku EO; May AG; Hall TC; Linke CA
    Transplantation; 1971 Oct; 12(4):249-52. PubMed ID: 4939817
    [No Abstract]   [Full Text] [Related]  

  • 69. Synthesis of 1-beta-L-arabinofuranosylcytosine, the enantiomer of cytosine arabinoside.
    Tolman RL; Robins RK
    J Med Chem; 1971 Nov; 14(11):1112. PubMed ID: 5286580
    [No Abstract]   [Full Text] [Related]  

  • 70. Chemotherapy of a murine neuroblastoma model.
    Murphy GP; Williams P; Keogh B
    J Surg Oncol; 1975; 7(6):521-4. PubMed ID: 1186269
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Solid intraperitoneal Landschütz tumour in mice: implications in cancer chemotherapy and immunology studies.
    Hod I; Zimber A; Gidoni D; Schonfeld S
    Lab Anim; 1975 Oct; 9(4):319-27. PubMed ID: 1207037
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Mouse cytomegalovirus infection under cytosine arabinoside treatment].
    Peller P; Goetz O; Rath M
    Infection; 1976; 4(3):130-3. PubMed ID: 185154
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Studies on drug resistance. II. Kinase patterns in P815 neoplasms sensitive and resistant to 1-beta-D-arabinofuranosylcytosine.
    Drahovsky D; Kreis W
    Biochem Pharmacol; 1970 Mar; 19(3):940-4. PubMed ID: 5534114
    [No Abstract]   [Full Text] [Related]  

  • 74. Combination therapy with thioguanine (NSC-752) and azaserine (NSC-742) for multiple myeloma.
    Hayes DM; Costa J; Moon JH; Hoogstraten B; Harley JB
    Cancer Chemother Rep; 1967 Aug; 51(4):235-8. PubMed ID: 5623733
    [No Abstract]   [Full Text] [Related]  

  • 75. Detection of induced resistance to cytosine-arabinoside with a short-term test.
    Volm M; Maas E; Mattern J
    Eur J Cancer (1965); 1980 May; 16(5):733-6. PubMed ID: 7389798
    [No Abstract]   [Full Text] [Related]  

  • 76. Biochemical approaches to the combination chemotherapy of colon cancer.
    Sartorelli AC; Shansky CW; Rosman M
    Cancer; 1975 Dec; 36(6 Suppl):2445-8. PubMed ID: 764962
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Thymidine enhancement of 1-beta-d-arabinofuranosylcytosine activity for mouse EL4 tumors.
    Reiter H
    Leuk Res; 1981; 5(3):259-63. PubMed ID: 7266020
    [No Abstract]   [Full Text] [Related]  

  • 78. Enhancement of the cancer chemotherapeutic effect of the cell cycle phase specific agents methotrexate and cytosine arabinoside when given as a water-oil-water emulsion.
    Benoy CJ; Schneider R; Elson LA; Jones M
    Eur J Cancer (1965); 1974 Jan; 10(1):27-33. PubMed ID: 4435002
    [No Abstract]   [Full Text] [Related]  

  • 79. The correlation of maximal drug dose, tumor recruitment, and sequence timing with therapeutic advantage: schedule-dependent toxicity of cytosine arabinoside.
    Burke PJ; Vaughan WP; Karp JE; Saylor PL
    Med Pediatr Oncol; 1982; 10 Suppl 1():201-8. PubMed ID: 7162462
    [No Abstract]   [Full Text] [Related]  

  • 80. Interaction of methotrexate and cytosine arabinoside.
    Tattersall MH; Connors TA; Harrap KR
    Lancet; 1972 Dec; 2(7791):1378-9. PubMed ID: 4118256
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.